World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
40602
World Ranking
6550
National Ranking
3478

Neil E. Kay publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Neil E. Kay sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 797 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Neil E. Kay D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Neil E. Kay sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Neil E. Kay is affiliated with the Mayo Clinic in the United States. Their research predominantly centers on medicine, with a significant focus on genetics, pathology and forensic medicine, immunology, oncology, and molecular biology. Within these fields, their work extensively addresses chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, CAR-T cell therapy research, advanced breast cancer therapies, acute lymphoblastic leukemia research, and gastrointestinal tumor research and treatment.

The scientist has contributed to numerous publications, with a strong presence in high-impact journals. Frequent publication venues include Blood, Cancer Research, Leukemia, Blood Cancer Journal, and Journal of Clinical Oncology.

Recent research papers authored or co-authored by Neil E. Kay include:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial, 2022, Blood
  • Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma, 2022, Blood
  • Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia, 2020, Molecular Therapy
  • Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia, 2020, Leukemia Research

The scientist collaborates frequently with several co-authors, such as Sameer A. Parikh, Susan L. Slager, Kari G. Rabe, Saad S. Kenderian, and Esteban Braggio, reflecting teamwork on multiple projects across their research career.

Neil E. Kay's main fields of study encompass Medicine with over 400 publications, further branching into subfields with considerable research output in Genetics (172 publications), Pathology and Forensic Medicine (81 publications), Immunology (63 publications), Oncology (45 publications), and Molecular Biology (28 publications).

The main topics that appear consistently across their work include:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • CAR-T cell therapy research
  • Advanced Breast Cancer Therapies
  • Acute Lymphoblastic Leukemia research
  • Gastrointestinal Tumor Research and Treatment

Best Publications

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson

  • Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group

    Bruce D. Cheson;John M. Bennett;Kanti R. Rai;Michael R. Grever

  • GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

    Rosalie M. Sterner;Reona Sakemura;Michelle J. Cox;Nan Yang

  • Diagnostic criteria for monoclonal B-cell lymphocytosis.

    Gerald E. Marti;Andy C. Rawstron;Paolo Ghia;Peter Hillmen

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

    Wei Ding;Betsy R. LaPlant;Timothy G. Call;Sameer A. Parikh

  • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

    Neil E. Kay;Susan M. Geyer;Timothy G. Call;Tait D. Shanafelt

  • Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

    Laura Z. Rassenti;Sonia Jain;Michael J. Keating;William G. Wierda

  • Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

    Rafael Fonseca;Emily A. Blood;Emily A. Blood;Martin M. Oken;Martin M. Oken;Robert A. Kyle;Robert A. Kyle

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

    John C Byrd;Peter Hillmen;Paolo Ghia;Arnon P Kater

  • Association of a microRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-cell Chronic Lymphocytic Leukemia

    Muller Fabbri;Arianna Bottoni;Masayoshi Shimizu;Riccardo Spizzo

  • Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

    Natali Pflug;Jasmin Bahlo;Tait D. Shanafelt;Barbara F. Eichhorst

  • Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Thomas E. Witzig;Stephanie R. Fink;Robert B. Jenkins

  • Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.

    Tait D. Shanafelt;Susan M. Geyer;Neil E. Kay

  • Chronic Lymphocytic Leukemia

    Neil E. Kay;Terry J. Hamblin;Diane F. Jelinek;Gordon W. Dewald

  • Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

    Gordon W. Dewald;Stephanie R. Brockman;Sarah F. Paternoster;Nancy D. Bone

  • VEGF Receptor Phosphorylation Status and Apoptosis is Modulated by a Green Tea Component, Epigallocatechin-3-gallate (EGCG) in B cell Chronic Lymphocytic Leukemia

    Yean K. Lee;Nancy D. Bone;Ann K. Strege;Tait D. Shanafelt

Frequent Co-Authors

Tait D. Shanafelt
Tait D. Shanafelt Stanford University
Susan L. Slager
Susan L. Slager Mayo Clinic
Diane F. Jelinek
Diane F. Jelinek Mayo Clinic
Kari G. Rabe
Kari G. Rabe Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
James R. Cerhan
James R. Cerhan Mayo Clinic
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Thomas E. Witzig
Thomas E. Witzig Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The landscape of medical education is evolving, with more students exploring online degrees to advance their healthcare careers. For those interested in healthcare administration, pursuing a cahme accredited online mha can open doors to leadership roles in hospitals, clinics, and public health organizations.

Registered nurses looking to further their credentials may consider an rn to bsn online without clinicals program. These flexible pathways are designed for working professionals and may minimize time away from work.

For nurses aiming for the highest level of practice, programs like the shortest msn to dnp program provide a fast track to a Doctor of Nursing Practice degree. Additionally, some online dnp programs without clinicals offer a streamlined experience for experienced practitioners seeking leadership or academic roles.

With these diverse online routes, you can align your medical education with your career goals and lifestyle, making advanced healthcare degrees more accessible than ever.

Best Scientists Citing Neil E. Kay

Trending Scientists